Regulatory ImpactRegulatory Impact
Regulatory InsightsRegulatory History

Vancomycin: Seven Decades of US Regulatory History, Patent Strategy, and Generic Competition

Regulatory ImpactNovember 10, 202617 min
VancomycinFDAGeneric DrugsAntibioticsPatent Strategy505(b)(2)Abbreviated New Drug ApplicationsDrug ShortagesPharmaceutical ManufacturingMarket Access

Executive Summary

Vancomycin provides an unusually extensive example of pharmaceutical regulatory evolution. Its original development preceded the modern FDA requirement for demonstrated efficacy, while its subsequent commercial history spans the Drug Efficacy Study Implementation program, specialized antibiotic approval procedures, the establishment of modern generic drug regulation, and the use of new drug applications for alternative formulations.

Generic competition developed differently across vancomycin's dosage forms. Injectable powders entered a market with multiple approved manufacturers decades before generic oral capsules became available. The latter required resolution of a major dispute over bioequivalence testing and regulatory exclusivity. Subsequent development concentrated on oral solutions, additional injectable strengths, storage characteristics, preparation requirements, and ready to use presentations.

The contemporary US market includes both mature generic products and formulations supported by more recent new drug applications. The history highlights several recurring regulatory considerations: the importance of reference product selection, the scientific requirements for bioequivalence, the potential for formulation patents to extend commercial protection, and the continuing influence of manufacturing quality and supply reliability.

The Original Patent and the 1958 Approval

Vancomycin's documented US patent history begins with an application filed on September 16, 1955, by Mack H. McCormick and James M. McGuire, assigned to Eli Lilly and Company. The application eventually issued as US Patent 3,067,099, titled 'Vancomycin and Method for Its Preparation,' on December 4, 1962. The patent described antibiotic substances produced by a microorganism then identified as Streptomyces orientalis, together with methods for preparing the antibiotic. The patent filing preceded FDA marketing approval, while patent issuance followed it by approximately four years. 1

The original US regulatory authorization was associated with Eli Lilly's New Drug Application (NDA) 11-520, which became effective in 1958. The product was marketed as Vancocin, initially for intravenous treatment of serious bacterial infections. A later Securities and Exchange Commission filing confirms that the original Lilly NDA subsequently ceased to be effective following voluntary action by Lilly. NDA 11-520 should therefore be distinguished from later applications and antibiotic certifications that supported continuing commercialization of vancomycin products. 23

Vancomycin entered the US market under a regulatory framework that required proof of safety before marketing but had not yet established the general requirement for substantial evidence of effectiveness. The Kefauver-Harris Drug Amendments of 1962 introduced the requirement to demonstrate effectiveness, leading FDA to reevaluate previously approved products through the Drug Efficacy Study Implementation (DESI) program. Vancomycin became part of this broader reassessment of established medicines. 45

The 1969 Efficacy Review and Early Generic Regulation

On December 9, 1969, FDA published a DESI notice addressing vancomycin hydrochloride injection under NDA 11-520. Following consideration of the National Academy of Sciences and National Research Council evaluation, FDA concluded that intravenous vancomycin was effective for severe staphylococcal infections that were potentially life threatening and could not be adequately treated with other effective, less toxic antimicrobial agents. FDA requested revised labeling within 60 days and addressed the continued certification of products containing vancomycin hydrochloride. The notice establishes an identifiable transition between the original approval and the subsequent federal determination of effectiveness. 3

Vancomycin's early generic history also reflects the specialized regulation of antibiotic products. Before the modern abbreviated new drug application system became fully applicable to antibiotics, antibiotic certification and Form 6 procedures supported additional products. An agreement filed with the Securities and Exchange Commission in 2004 describes how approved antibiotic Form 6 applications were treated as abbreviated new drug applications under 1982 FDA regulations. Legislative changes in 1997 eliminated the separate antibiotic approval provisions and associated antibiotic monograph regulations. These historical procedures help explain why several early vancomycin products appear under abbreviated application numbers despite having originated before the modern generic approval system. 26

The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Amendments, established the modern generic framework under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Under that system, an abbreviated new drug application (ANDA) ordinarily relies on FDA's prior finding of safety and effectiveness for a reference listed drug (RLD), while demonstrating the required pharmaceutical equivalence, bioequivalence, manufacturing quality, and labeling consistency. Vancomycin's later development demonstrates how these requirements operate differently across oral and injectable dosage forms. 67

How the Dosage Forms Developed

Vancomycin's US market now includes several distinct pharmaceutical presentations. Intravenous products include lyophilized powder in vials, premixed infusion solutions, and concentrated pharmacy bulk packages. Oral formulations include capsules and powders supplied for preparation as oral solutions. These formulations address different administration, storage, preparation, and dispensing requirements. The intended route is clinically significant because oral vancomycin is poorly absorbed under usual conditions and is used primarily for infections within the gastrointestinal tract, while intravenous administration provides systemic exposure. 891011

In pharmaceutical terminology, a small volume parenteral (SVP) contains 100 mL or less, while a large volume parenteral (LVP) contains more than 100 mL. The classification concerns the labeled solution volume. A 100 mL premixed infusion bag is therefore within the small volume category, while a 200 mL bag is within the large volume category. A vial of concentrated or powdered vancomycin may require further dilution before intravenous infusion, regardless of its original container volume. 121310

PresentationRepresentative US regulatory historyFormulation and commercial characteristics
Injectable powder in vialsEarly antibiotic approvals and subsequent ANDAs, including ANDA 060180 and later generic applicationsLyophilized powder for reconstitution and dilution. Products include conventional vial strengths and larger pharmacy supply presentations.
Frozen premixed intravenous solutionBaxter NDA 050671; premixed GALAXY container presentations approved beginning in 1993Infusion bags containing vancomycin in dextrose or sodium chloride solutions. Frozen storage and thawing requirements affect handling.
Room temperature premixed infusionNDA 211962, originally approved February 15, 2019Ready to use 5 mg/mL solutions in flexible bags, with approved dose presentations extending from 500 mg/100 mL to 2 g/400 mL.
Concentrated pharmacy bulk solutionNDA 213895, approved August 26, 20215 g/100 mL solution for pharmacy admixture preparation. The bulk package is subject to specific handling and dilution instructions.
Oral capsulesNDA 050606, approved April 15, 1986125 mg and 250 mg capsules for approved gastrointestinal indications; generic capsule approvals began in April 2012.
Traditional oral solutionANDA 061667, approved in 1972; another oral solution under ANDA 063321 approved in 1993Earlier oral solution products were subsequently withdrawn or discontinued. Later generic development renewed this presentation.
Oral solution kitsNDA 208910, approved January 26, 2018Powder and diluent kits producing 25 mg/mL or 50 mg/mL oral solution; subsequent generic products reference the approved formulation.

Oral Capsules and the 2012 Generic Dispute

FDA approved Vancocin oral capsules under NDA 050606 on April 15, 1986. The formulation provided 125 mg and 250 mg capsules for gastrointestinal infections, including Clostridioides difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus. Because vancomycin ordinarily has limited absorption after oral administration, systemic plasma concentrations provide an imperfect measure of the amount of active drug available within the gastrointestinal tract. This characteristic subsequently became central to the scientific debate over generic capsule bioequivalence. 89

ViroPharma acquired rights to Vancocin capsules in 2004 and subsequently contested FDA's approach to approving generic versions. The regulatory disagreement focused on whether laboratory dissolution testing could establish bioequivalence or whether comparative clinical studies in patients were necessary. FDA's position evolved as the agency considered the high solubility of vancomycin and the suitability of in vitro testing for locally acting gastrointestinal products. ViroPharma argued that the proposed approach was inadequate and filed a series of citizen petitions and legal challenges. 1415

On April 9, 2012, FDA denied ViroPharma's citizen petition and approved three ANDAs for generic vancomycin hydrochloride capsules. The approvals included applications associated with Akorn, Alvogen, and Watson Laboratories. The agency also denied ViroPharma's request for an additional three years of exclusivity related to labeling changes approved in December 2011. FDA determined that the changes refined previously approved conditions of use and did not establish the additional exclusivity requested for an older antibiotic. 1615

ViroPharma challenged the approvals in federal court, asserting both statutory exclusivity and bioequivalence claims. The US District Court for the District of Columbia denied a preliminary injunction in April 2012 and rejected the renewed challenges in a January 9, 2013 opinion. The dispute established an important regulatory example of FDA's discretion to select scientifically appropriate bioequivalence methods for a product acting locally in the gastrointestinal tract. 157

The Federal Trade Commission subsequently brought allegations concerning ViroPharma's petitioning strategy. In a 2017 complaint, the Commission alleged that repetitive filings had delayed generic competition and described 43 FDA filings and three lawsuits between 2006 and 2012. These statements were allegations made by the Commission and should be understood separately from FDA's scientific determinations and the district court's adjudication of the 2012 generic approvals. 14

The Return of Oral Solutions

Oral vancomycin solutions have a regulatory history that predates the capsule formulation. FDA's review of a later oral solution application identifies ANDA 061667, approved in 1972, and ANDA 063321, approved in 1993. Those products were subsequently discontinued or withdrawn from marketing. FDA also recognized that certain approved injectable vancomycin powders could be prepared for oral administration according to their labeling, providing an additional source of oral treatment when a commercially prepared solution was unavailable or unsuitable. 8

A new commercial approach emerged with Firvanq, approved on January 26, 2018, under NDA 208910. The original applicant was associated with CutisPharma and RxM Therapeutics, while the product is currently identified in labeling associated with Azurity Pharmaceuticals. Firvanq is supplied as a kit containing vancomycin hydrochloride powder and flavored diluent, yielding 25 mg/mL or 50 mg/mL after reconstitution. Its approved indications include C. difficile associated diarrhea and staphylococcal enterocolitis. 817

Firvanq used the section 505(b)(2) regulatory pathway. FDA's review identifies Vancocin capsules and an approved vancomycin injectable powder as listed drugs supporting reliance on previous findings of safety and effectiveness. Following regulatory discussions, including a May 13, 2015 meeting, the applicant pursued a scientific bridge supported by solubility, permeability, dissolution, and microbiological activity information. FDA's review describes the resulting approach as permitting reliance on the listed drugs without requiring a new comparative clinical efficacy trial. 8

The 2018 approval illustrates a recurring opportunity in the development of established pharmaceutical ingredients. Changes to the formulation, preparation process, and presentation can support a separate NDA, even when the underlying active ingredient and therapeutic indications are already established. The resulting regulatory strategy must address product specific pharmaceutical quality, the suitability of reliance on previously approved products, and the conditions required for safe administration. 86

New Injectable Formulations and Regulatory Challenges

Conventional vancomycin injectable powders continued to support development of additional strengths. Mylan submitted NDA 209481 under section 505(b)(2), seeking approval of lyophilized vancomycin hydrochloride for injection in 250 mg, 750 mg, 1.25 g, and 1.5 g vial presentations. FDA's 2017 review identified manufacturing and labeling deficiencies that prevented approval at that stage. The application subsequently received approval on July 10, 2018. The program demonstrates that relatively familiar dosage forms can require an NDA when the proposed product and its regulatory basis extend beyond the requirements of an ordinary generic application. 1819

Premixed intravenous vancomycin had already been established through Baxter's NDA 050671, including frozen solutions supplied in GALAXY containers. FDA's later review identifies April 1993 approvals for the 500 mg/100 mL and 1 g/200 mL presentations, with a 750 mg/150 mL presentation approved in December 2010. The frozen product required thawing before administration, creating a distinct handling requirement for hospitals and other infusion settings. 2013

Xellia Pharmaceuticals subsequently developed a ready to use formulation under NDA 211962. FDA approved the original application on February 15, 2019, with additional strengths approved in 2020. The new formulation could be stored below 25°C and used without the thawing required for Baxter's frozen formulation. The application used section 505(b)(2) and relied on an existing approved vancomycin product while supplying additional nonclinical information concerning formulation excipients. FDA's review also records Fast Track and Qualified Infectious Disease Product designations for the program. 2021

The Xellia program also demonstrates the regulatory consequences of excipient selection. FDA evaluated polyethylene glycol 400 and N-acetyl-D-alanine, together with other formulation constituents, as part of the safety assessment. The original approval included a boxed warning relating to potential embryo and fetal toxicity identified through nonclinical findings. In June 2025, FDA approved labeling changes that removed the boxed warning and revised other sections of the prescribing information. The currently marketed product is identified as Tyzavan, with labeling associated with Hikma Pharmaceuticals. The labeling history provides a concrete example of how product specific safety requirements may evolve after approval. 201022

Xellia also pursued NDA 213895 for vancomycin injection in a 5 g/100 mL pharmacy bulk package. FDA issued a Complete Response Letter on March 20, 2020, following deficiencies in the assessment of substances that could migrate from the packaging into the drug product. The sponsor resubmitted the application on February 26, 2021, including additional data concerning leachables and their safety. FDA approved the application on August 26, 2021. This review demonstrates the importance of container closure compatibility, extractables and leachables evaluation, and the specific requirements of concentrated pharmacy bulk presentations. 11

The Modern Generic Pipeline

Recent generic approvals show that vancomycin development has continued across both oral and intravenous products. For generic manufacturers, the relevant competitive market depends on the reference listed drug, strength, route, and dosage form. FDA's Orange Book and approval records therefore distinguish generic capsules, oral solutions, injectable powders, and separate NDA products. An approval for one presentation does not automatically establish therapeutic equivalence across the entire vancomycin product family. 76

On November 14, 2022, FDA approved Alkem Laboratories' ANDA 214913 for vancomycin hydrochloride oral solution in 25 mg/mL and 50 mg/mL strengths, referencing Firvanq. The approval letter identifies a Complete Response Letter issued September 29, 2021, followed by an ultimately successful resubmission. FDA determined that the approved generic was bioequivalent and therapeutically equivalent to the reference product. The approval established a new generic pathway for a formulation whose original branded approval dated only to 2018. 23

The 2022 approval is particularly notable for its patent history. FDA listed six patents associated with the reference product, each then carrying a stated expiration date of March 13, 2035. Alkem submitted paragraph IV certifications asserting that the patents were invalid, unenforceable, or would not be infringed by its proposed product. Litigation concerning one of the patents had been dismissed. FDA identified Alkem as eligible for 180 days of generic exclusivity, subject to subsequent statutory conditions and potential forfeiture. The approval letter establishes generic authorization while also documenting the separate patent and exclusivity considerations affecting commercial entry. 23

In June 2023, additional abbreviated approvals reached the market. FDA's Competitive Generic Therapy records identify Amneal Pharmaceuticals' ANDA 215338 for a 50 mg/mL oral solution referencing an earlier vancomycin oral solution application, and Hikma's ANDA 217489 for 1.25 g and 1.5 g injectable vials referencing NDA 209481. FDA recorded commercial marketing dates of June 23 and August 16, 2023, respectively, for these products. Both applications were identified as eligible for Competitive Generic Therapy exclusivity at approval. 24

Further expansion continued in 2025 and 2026. Glenmark announced the US launch of generic injectable vancomycin in 750 mg, 1.25 g, and 1.5 g vial presentations in April 2025. In August 2026, Aurobindo Pharma announced FDA approval for 25 mg/mL and 50 mg/mL oral solutions referencing Firvanq, and its product labeling identifies ANDA 218130. These developments demonstrate continuing competition within newer formulation and strength segments as well as the established injectable market. 2526

DateApplicationProduct or regulatory eventSignificance
1958NDA 11-520Original Lilly vancomycin approvalEstablished the original US antibiotic authorization.
1964ANDA 060180Injectable vancomycin antibiotic applicationIllustrates the early regulatory pathway for additional antibiotic products.
1972ANDA 061667Vancomycin hydrochloride oral solutionEarly approved oral solution presentation.
April 15, 1986NDA 050606Vancocin oral capsulesEstablished the reference product for later generic oral capsules.
April 9, 2012Three ANDAsGeneric vancomycin capsulesGeneric entry followed FDA's resolution of bioequivalence and exclusivity disputes.
January 26, 2018NDA 208910Firvanq oral solution kitNew oral formulation approved through section 505(b)(2).
July 10, 2018NDA 209481Additional injectable vial strengthsNew NDA supported development of alternative injectable presentations.
February 15, 2019NDA 211962Xellia ready to use infusion solutionRoom temperature storage and premixed administration.
August 26, 2021NDA 213895Vancomycin pharmacy bulk packageConcentrated 5 g/100 mL product following resolution of packaging related deficiencies.
November 14, 2022ANDA 214913Alkem oral solutionGeneric approval referencing Firvanq, with paragraph IV patent certifications.
June 23, 2023ANDA 215338Amneal oral solutionCompetitive Generic Therapy approval for a 50 mg/mL oral solution.
June 29, 2023ANDA 217489Hikma injectable vialsCompetitive Generic Therapy approval for 1.25 g and 1.5 g injectable presentations.
April 1, 2025Commercial launchGlenmark injectable vancomycinAdded commercial competition for selected vial strengths.
August 2026ANDA 218130Aurobindo oral solutionFurther generic competition referencing Firvanq.

Commercial Evolution and Market Structure

Vancomycin's commercial history reflects changes in the value of individual formulations as competition developed. Immediately before generic capsule entry, Akorn cited IMS Health data estimating approximately $328 million in US Vancocin capsule sales for the 12 months ended December 31, 2011. The figure represents the branded capsule market at that time, immediately before the April 2012 generic approvals. It provides historical context for the commercial significance of the subsequent bioequivalence and exclusivity dispute. 2716

The injectable market has a different competitive structure, with numerous manufacturers supplying established vial presentations and additional companies introducing newer dosage strengths. In its April 2025 launch announcement, Glenmark cited IQVIA data estimating approximately $39.3 million in annual US sales for the specific 750 mg, 1.25 g, and 1.5 g injectable vial segment during the 12 months ending January 2025. This figure is a manufacturer reported estimate for a defined subset of injectable vancomycin products. It does not represent total US vancomycin sales and is not directly comparable to the 2011 branded capsule figure. 25

Clinical treatment recommendations also influence the oral market. The 2021 guidance from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America conditionally recommends fidaxomicin over a standard course of vancomycin for an initial episode of C. difficile infection, while retaining oral vancomycin as an acceptable alternative. For recurrent infection, the guidance also recognizes several vancomycin regimens. These recommendations place oral vancomycin within a market shaped by treatment effectiveness, recurrence prevention, product availability, and medication acquisition costs. 28

The competitive environment continues to develop. FDA records identify an October 7, 2026 approval of a generic fidaxomicin tablet application referencing Dificid. Although commercial availability and the resulting market impact require separate assessment, this approval adds another regulatory development relevant to the broader C. difficile treatment market. 2428

Across the injectable market, procurement decisions may also reflect preparation requirements, storage conditions, available strengths, and supply continuity. Conventional vial products require pharmacy preparation, while ready to use infusion bags offer different workflows. Baxter's frozen formulation and the room temperature formulation developed under NDA 211962 further demonstrate how the same active ingredient can support products with materially different handling requirements. A consolidated estimate of the entire US vancomycin market in 2026, including all dosage forms, manufacturers, channels, and net prices, remains unspecified. 132010

Manufacturing Quality, Safety, and Supply Reliability

Vancomycin's regulatory history also demonstrates the continuing importance of pharmaceutical quality after generic competition has been established. FDA's evaluations of newer injectable formulations identified concerns involving excipient toxicology, packaging compatibility, and leachables. The 2020 Complete Response Letter for the concentrated pharmacy bulk product illustrates how these requirements can delay approval even when the active ingredient and intended indications are established. These considerations are particularly relevant to sterile injectable products, where contamination and packaging failures can have immediate consequences for patients. 112012

On November 9, 2026, FDA published a company announcement concerning a voluntary nationwide recall by Eugia US LLC of one lot of vancomycin hydrochloride for injection, 1.25 g in a 30 mL single dose vial. The recall followed identification of particulate matter described as a glass particle. The manufacturer reported that the affected lot had been distributed to wholesalers in September 2026. The recall demonstrates that established generic products remain subject to significant manufacturing and container quality risks. 29

Product labels also continue to emphasize clinical safety considerations. Intravenous vancomycin labeling identifies risks that include infusion reactions, nephrotoxicity, ototoxicity, and severe dermatologic reactions. The Tyzavan label requires intravenous infusion over at least 60 minutes and provides specific instructions concerning appropriate dose selection. Oral vancomycin labels recognize that systemic absorption may occur in some patients with active intestinal disease, potentially requiring additional monitoring. These requirements contribute to the operational distinctions among formulations. 10917

The commercial implications of quality and supply risks extend beyond the affected manufacturer. Hospital formulary and purchasing decisions must account for the availability of appropriate strengths, the ability to prepare and administer the product safely, and the stability of supply. Regulatory approval establishes authorization to market a formulation, while ongoing manufacturing performance and distribution determine its practical availability. 29610

Regulatory Lessons for Established Drug Development

Vancomycin's development history demonstrates that an established active pharmaceutical ingredient can support several distinct regulatory strategies. The original product established a foundational safety authorization that later required efficacy reassessment. Generic injectable and oral products used abbreviated approval procedures, while new presentations used section 505(b)(2) applications supported by previous findings of safety and effectiveness and additional evidence specific to their formulations. The appropriate pathway depends on the particular product and the evidence needed to support its proposed conditions of use. 248206

The oral capsule dispute demonstrates how scientific methodology can influence market entry. FDA's acceptance of laboratory dissolution testing for generic oral vancomycin capsules was central to the 2012 approvals, while the subsequent litigation concerned both the evidence supporting bioequivalence and the availability of statutory exclusivity. The case illustrates the commercial importance of product specific bioequivalence recommendations, regulatory petitions, and the precise scope of previously approved conditions of use. 1516

The newer formulation programs demonstrate separate challenges. Oral solution applicants had to establish an appropriate scientific bridge to approved products, developers of new injectable formulations had to qualify novel excipients, and concentrated pharmacy bulk products required adequate assessment of packaging related impurities. More recent generic approvals also show that formulation patents and paragraph IV certifications can remain relevant long after the original molecule patent has expired. These requirements create opportunities for pharmaceutical development while imposing distinct regulatory and commercial obligations. 8201123

Conclusion

Vancomycin's US regulatory history spans nearly seven decades, beginning with its original patent and approval and continuing through efficacy reassessment, the introduction of generic competition, and the development of new dosage forms. Each phase reflects a different regulatory consideration, from demonstrating clinical effectiveness to establishing bioequivalence, qualifying formulation components, and managing the legal requirements associated with generic entry.

The 2012 capsule approvals represent a particularly consequential intersection of regulatory science and commercial competition. Subsequent oral solution and injectable formulation programs demonstrate how pharmaceutical development can continue after an active ingredient becomes widely established. The current market contains several distinct product segments with different reference products, manufacturing requirements, and competitive conditions.

For developers and regulatory strategists, vancomycin illustrates the continuing importance of product specific evidence. Formulation design, delivery requirements, scientific bridging, patent certifications, and pharmaceutical quality can determine the regulatory pathway and commercial prospects of a medicine long after its original approval.